ArticleBiomedicines2024

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience.

Aaron Trando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.